HomeNYSE:JNJ

NYSE:JNJ

J&J’s Oral Pill Shows Promise for Depression and Insomnia Symptoms

J&J’s Oral Pill Shows Promise for Depression and Insomnia Symptoms

May 30, 2024

JNJ Receives Full FDA Approval for Rybrevant in Lung Cancer Treatment

JNJ Receives Full FDA Approval for Rybrevant in Lung Cancer Treatment

March 4, 2024

Johnson & Johnson Anticipates Up to 6% Sales Growth in 2024

Johnson & Johnson Anticipates Up to 6% Sales Growth in 2024

December 5, 2023

Johnson & Johnson Seeks Expanded Approval for Rybrevant in Lung Cancer Treatment

Johnson & Johnson Seeks Expanded Approval for Rybrevant in Lung Cancer Treatment

November 21, 2023

JNJ Stock Rose on Wall Street’s Talc Case Settlement Optimism

JNJ Stock Rose on Wall Street’s Talc Case Settlement Optimism

April 5, 2023